HDAC9 and atherosclerosis: Valproate, a broad-spectrum HDAC inhibitor, has been shown to inhibit atherosclerosis in animal models.124 Nonspecific HDAC inhibitors, however, have contraindications that prevent their direct usage in the treatment of atherosclerosis.